OHSU Knight Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, OHSU Knight Cancer Institute sits in the top decile of US sponsors by registered trial count (#150 of 15,742 sponsors by registered trial count).
OHSU Knight Cancer Institute: 211 sponsored US clinical trials, 35 recruiting.
OHSU Knight Cancer Institute sponsors 211 registered US clinical trials on ClinicalTrials.gov, 35 of them currently recruiting, and 94 completed. 5 of these trials are in Phase 3-4 (later-stage) and 114 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 6 trials.
Top-decile sponsor footprint
OHSU Knight Cancer Institute ranks in the top decile of sponsors by registered trial count (#150 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
94 of 149 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (63.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
211 total, page 2 of 5
MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
NCT03699995
Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery
NCT03361436
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
NCT02522715
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
NCT02312557
Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor
NCT07660666
Peer Support Program for Improving Quality of Life Among Head and Neck Patients, Connecting Through Cancer Trial
NCT07664241
A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatment of Chronic Pancreatitis and Benign Pancreatic Tumors
NCT05453851
Phase I Randomized Controlled Trial of Functional Resistance Training in Older Cancer Survivors: The ACES Trial
NCT07606313
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
NCT07511504
Mammogram Pretreatment With Ulipristal Acetate
NCT07434128
Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT
NCT07498517
An Exercise Intervention for Improving Mental and Physical Health in Patients With Primary Brain Tumors and Their Caregivers, ET-NEURO Trial
NCT07278440
An Exercise Prehabilitation Intervention for Improving Mobility and Recovery Outcomes in Patients Undergoing Head and Neck Cancer Surgery
NCT06079697
At-Home Dermoscopy Artificial Intelligence
NCT05321784
Enhancing Skin Cancer Early Detection and Treatment in Primary Care
NCT05675709
Use of Virtual Reality Goggles During Chemotherapy Infusion to Reduce Anxiety-Related Symptoms
NCT05793957
Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy
NCT04965311
The Use of "Smart" Body-Weight Scales for Weight and Nutritional Monitoring in Patients With Head and Neck Cancer Undergoing Radiation Therapy
NCT05457478
Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma
NCT05458869
Humidified Forest Oils for Immune System Recovery in Stage I-III Breast or Prostate Cancer
NCT05012813
Telehealth & HPV Self-Collection
NCT05089825
Effects of Simulated Solar Radiation on Human Skin in Preventing Skin Cancer
NCT05027009
A Digital Intervention Protocol to Enhance Recovery After Head and Neck Surgery
NCT04814524
Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
NCT04481113
Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC
NCT04890054
Virtual Reality Experiences for Anxiety and Pain Control
NCT04759183
Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy
NCT04465760
Predicting the Impact of Treatment Toxicities on Health During Cancer ( PATTERN )
NCT05790538
Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer
NCT04400903
Virtual Reality for the Education of Cancer Patients Undergoing Radiation Therapy
NCT04278534
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
NCT03878524
Hyperspectral Endoscopy Imaging for the Early Detection of Precancerous Lesions in Average Risk Patients
NCT04172493
Whole Body Vibration for the Improvement of Health and Functioning in Participants With Chemotherapy-Induced Peripheral Neuropathy
NCT04170075
Progressive Resistance Training for the Improvement of Physical Function
NCT04247425
Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer
NCT03995667
Pain Management for Head and Neck Cancer Survivors
NCT05115825
Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
NCT03812289
GET FIT Prostate: A Randomized Controlled Exercise Trial
NCT03741335
EXERCISING TOGETHER for Couples Coping With Cancer
NCT03630354
JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia
NCT03557970
Exercise Program Among Lung Cancer Dyads
NCT03649737
Video Distraction to Decrease Use of Sedation in Pediatric Participants During Radiation Therapy
NCT03677531
Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer
NCT03544125
Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer
NCT03280277
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
NCT03347617
Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases
NCT03325166
Exercising Together During Radiation Treatment
NCT03418025
Provider Training in Increasing Patient Tobacco Cessation Counseling and Referrals for Patients With Cancer Undergoing Radiation Therapy
NCT03135782
Internet-Based Exercise and Diet Support in Prostate Cancer Survivors
NCT03406013
Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant
NCT03097588
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 41 |
| Phase 2 | 73 |
| Phase 3 | 2 |
| Phase 4 | 3 |
Therapeutic Areas
What is open in the OHSU Knight Cancer Institute pipeline
35 recruiting of 211 indexed (17% open); 94 completed (45%).
Phase mix: 5 late (III/IV) vs 114 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
OHSU Knight Cancer Institute: open-pipeline peers nationwide
Peers matched on 211 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
OHSU Knight Cancer Institute sits below the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 211 trials (± recruiting share)
- MedImmune · 210 trials · 0% recruiting
- University of Louisville · 217 trials · 21% recruiting
- Florida State University · 219 trials · 21% recruiting
- Penn State University · 219 trials · 17% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Rush University Medical Center · 17% recruiting · 320 trials
- Massachusetts General Hospital · 17% recruiting · 2,032 trials
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
Related
What to do with this OHSU Knight Cancer Institute page
211 registered trials is a research-attention snapshot, not an endorsement of OHSU Knight Cancer Institute or any single study.
- 35 of OHSU Knight Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Myeloid Leukemia is the condition OHSU Knight Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
OHSU Knight Cancer Institute pipeline card: 211 registered trials from official public datasets.Report a data error.